SCHEMBL935646

SCHEMBL935646

O=C(O)CNC(=O)Cc1ccc(O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.61
CAMK2A Q9UQM7 1/20 0.61
LMNA P02545 3/20 0.58
ALDH1A1 P00352 3/20 0.58
TRPV1 Q8NER1 1/20 0.54
CDK5 Q00535 1/20 0.51
CDK5R1 Q15078 1/20 0.51
FNTA P49354 1/20 0.50
FNTB P49356 1/20 0.50
ESRRB O95718 1/20 0.50
ESRRG P62508 1/20 0.50
RAB9A P51151 2/20 0.49
NPC1 O15118 1/20 0.49
ERCC1 P07992 1/20 0.46
ERCC4 Q92889 1/20 0.46
ATM Q13315 1/20 0.46
CTBP2 P56545 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
BCHE P06276 1/20 0.44
ACHE P22303 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenaceturic Acid SCHEMBL196523 0.84 ATM (0.62) LMNAALDH1A1TRPV1RAB9AERCC1
Phenaceturic Acid SCHEMBL14126285 0.84 ATM (0.62) LMNAALDH1A1TRPV1RAB9AERCC1
SCHEMBL17084616 0.83 MAPT (0.58) CA2LMNAALDH1A1RAB9AATM
SCHEMBL11632040 0.83 ALDH1A1 (0.56) CA2LMNAALDH1A1RAB9AATM
SCHEMBL8277220 0.83 ALDH1A1 (0.60) LMNAALDH1A1RAB9ANPC1ATM
SCHEMBL3199912 0.81 ATM (0.60) CA2CAMK2ALMNAALDH1A1TRPV1
SCHEMBL1221588 0.81 HDAC2 (0.57) CA2CAMK2AALDH1A1TRPV1ERCC1
SCHEMBL11288698 0.81 ATM (0.59) LMNAALDH1A1TRPV1RAB9AATM
SCHEMBL13058961 0.80 ESRRB (0.54) CA2CAMK2ALMNAALDH1A1TRPV1
SCHEMBL4888845 0.79 CDK5 (0.61) CA2CAMK2ALMNAALDH1A1TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025072741-A1 PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-04-03 WO claimed
EP-4424365-A2 PET FOOD COMPOSITIONS Hill's Pet Nutrition, Inc. (US) 2024-09-04 EP claimed
EP-4017281-B1 PET FOOD COMPOSITIONS HILLS PET NUTRITION INC (US) 2024-08-28 EP claimed
US-20230233620-A1 HIGH-COMPLEXITY SYNTHETIC GUT BACTERIAL COMMUNITIES Kanvas Biosciences, Inc. 2023-07-27 US claimed
EP-4152959-A1 HIGH-COMPLEXITY SYNTHETIC GUT BACTERIAL COMMUNITIES Chan Zuckerberg Biohub, Inc. (US) 2023-03-29 EP claimed
CN-115094423-B Inorganic membrane removing liquid suitable for aluminum substrate circuit board and application thereof 深圳市板明科技股份有限公司 2022-11-08 CN claimed
CN-115094423-A Inorganic film removing liquid suitable for aluminum substrate circuit board and application thereof 深圳市板明科技股份有限公司 2022-09-23 CN claimed
CN-114828648-A Pet food compositions 希尔氏宠物营养品公司 2022-07-29 CN claimed
EP-4017281-A1 PET FOOD COMPOSITIONS Hill's Pet Nutrition, Inc. (US) 2022-06-29 EP claimed
WO-2021237162-A1 HIGH-COMPLEXITY SYNTHETIC GUT BACTERIAL COMMUNITIES CHAN ZUCKERBERG BIOHUB, INC. (US) 2021-11-25 WO claimed
WO-2021127701-A1 PET FOOD COMPOSITIONS HILL'S PET NUTRITION, INC. (US) 2021-06-24 WO claimed
US-20180203018-A1 METABOLIC BIOMARKERS OF CROHN'S DISEASE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-07-19 US claimed
US-20260034086-A1 Pet Food Compositions Comprising Caprylic Acid And Docosahexaenoic Acid And/Or Eicosapetaenoic Acid For Use In Treating Struvite Urolithiasis HILL'S PET NUTRITION, INC. (US) 2026-02-05 US disclosed
US-20250380721-A1 Pet Food Compositions HILL'S PET NUTRITION, INC. (US) 2025-12-18 US disclosed
US-12458617-B2 Pet food compositions comprising caprylic acid and docosahexaenoic acid and/or eicosapetaenoic acid for use in treating struvite urolithiasis HILL'S PET NUTRITION, INC. (US) 2025-11-04 US disclosed
EP-3709817-B2 COMPOSITIONS COMPRISING OMEGA-3 POLYUNSATURATED AND MEDIUM CHAIN FATTY ACIDS HILLS PET NUTRITION INC (US) 2025-10-22 EP disclosed
EP-0862557-A1 SYMMETRICAL bis-HETEROARYLMETHOXYPHENYLALKYL CARBOXYLATES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS Abbott Laboratories (US) 1998-09-09 EP disclosed
WO-1997012867-A1 SYMMETRICAL bis-HETEROARYLMETHOXYPHENYLALKYL CARBOXYLATES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS ABBOTT LABORATORIES (US) 1997-04-10 WO disclosed
EP-0733066-A1 PRETARGETING METHODS AND COMPOUNDS NEORX CORPORATION (US) 1996-09-25 EP disclosed
WO-1995015979-A1 PRETARGETING METHODS AND COMPOUNDS NEORX CORPORATION (US) 1995-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034086-A1 Pet Food Compositions Comprising Caprylic Acid And Docosahexaenoic Acid And/Or Eicosapetaenoic Acid For Use In Treating Struvite Urolithiasis FPR2, FPR1, FPR3 CA2 819/4885CAMK2A 1043/4885LMNA 1957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.